[1] Roundtree I A, Evans M E, Pan T, et al. Dynamic RNA Modifications in Gene Expression Regulation[J]. Cell, 2017, 169(7): 1187-1200. doi:10.1016/j.cell.2017.05.045.
[2] Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer[J]. J Hematol Oncol, 2019, 12(1): 121. doi:10.1186/s13045-019-0805-7.
[3] Wang Q, Chen C, Ding Q, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance[J]. Gut, 2020, 69(7): 1193-1205. doi:10.1136/gutjnl-2019-319639.
[4] Fu Y, Dominissini D, Rechavi G, et al. Gene expression regulation mediated through reversible m6A RNA methylation[J]. Nat Rev Genet, 2014, 15(5): 293-306. doi:10.1038/nrg3724.
[5] Wang H, Hu X, Huang M, et al. Mettl3-mediated mRNA m(6)A methylation promotes dendritic cell activation[J]. Nat Commun, 2019, 10(1): 1898. doi:10.1038/s41467-019-09903-6.
[6] Zhao B S, Roundtree I A, He C. Post-transcriptional gene regulation by mRNA modifications[J]. Nat Rev Mol Cell Biol, 2017, 18(1): 31-42. doi:10.1038/nrm.2016.132.
[7] Lin X, Chai G, Wu Y, et al. RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail[J]. Nat Commun, 2019, 10(1): 2065. doi:10.1038/s41467-019-09865-9.
[8] Rodriguez-Ruiz M E, Vitale I, Harrington K J, et al. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment[J]. Nat Immunol, 2020, 21(2): 120-134. doi:10.1038/s41590-019-0561-4.
[9] Minn A J, Wherry E J. Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling[J]. Cell, 2016, 165(2): 272-5. doi:10.1016/j.cell.2016.03.031.
[10] Topalian S L, Taube J M, Pardoll D M. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science, 2020, 367(6477). doi:10.1126/science.aax0182.
[11] Quail D F, Joyce J A. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-37. doi:10.1038/nm.3394.
[12] Vitale I, Manic G, Coussens L M, et al. Macrophages and Metabolism in the Tumor Microenvironment[J]. Cell Metab, 2019, 30(1): 36-50. doi:10.1016/j.cmet.2019.06.001.
[13] Goliwas K F, Deshane J S, Elmets C A, et al. Moving Immune Therapy Forward Targeting TME[J]. Physiol Rev, 2021, 101(2): 417-425. doi:10.1152/physrev.00008.2020.
[14] Deberardinis R J. Tumor Microenvironment, Metabolism, and Immunotherapy[J]. N Engl J Med, 2020, 382(9): 869-871. doi:10.1056/NEJMcibr1914890.
[15] Li M, Zha X, Wang S. The role of N6-methyladenosine mRNA in the tumor microenvironment[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188522. doi:10.1016/j.bbcan.2021.188522.
[16] Zhu J, Xiao J, Wang M, et al. Pan-Cancer Molecular Characterization of m(6)A Regulators and Immunogenomic Perspective on the Tumor Microenvironment[J]. Front Oncol, 2020, 10: 618374. doi:10.3389/fonc.2020.618374.
[17] Gu Y, Wu X, Zhang J, et al. The evolving landscape of N(6)-methyladenosine modification in the tumor microenvironment[J]. Mol Ther, 2021. doi:10.1016/j.ymthe.2021.04.009.
[18] Jiang Y, Wan Y, Gong M, et al. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway[J]. J Cell Mol Med, 2020, 24(11): 6137-6148. doi:10.1111/jcmm.15228.
[19] Chen G, Liu B, Yin S, et al. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA[J]. Oncogenesis, 2020, 9(9): 81. doi:10.1038/s41389-020-00265-z.
[20] Kaymak I, Williams K S, Cantor J R, et al. Immunometabolic Interplay in the Tumor Microenvironment[J]. Cancer Cell, 2021, 39(1): 28-37. doi:10.1016/j.ccell.2020.09.004.
[21] Colaprico A, Silva T C, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data[J]. Nucleic Acids Res, 2016, 44(8): e71. doi:10.1093/nar/gkv1507.
[22] Wilkerson M D, Hayes D N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking[J]. Bioinformatics, 2010, 26(12): 1572-3. doi:10.1093/bioinformatics/btq170.
[23] Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation[J]. Nucleic Acids Res, 2020, 48(7): 3816-3831. doi:10.1093/nar/gkaa048.
[24] Barbieri I, Kouzarides T. Role of RNA modifications in cancer[J]. Nat Rev Cancer, 2020, 20(6): 303-322. doi:10.1038/s41568-020-0253-2.
[25] Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells[J]. Nature, 2019, 566(7743): 270-274. doi:10.1038/s41586-019-0916-x.
[26] He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Mol Cancer, 2019, 18(1): 176. doi:10.1186/s12943-019-1109-9.
[27] Chen X Y, Zhang J, Zhu J S. The role of m(6)A RNA methylation in human cancer[J]. Mol Cancer, 2019, 18(1): 103. doi:10.1186/s12943-019-1033-z.
[28] Huang H, Weng H, Chen J. m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer[J]. Cancer Cell, 2020, 37(3): 270-288. doi:10.1016/j.ccell.2020.02.004.
[29] Zhou S, Wang L, Yang Q, et al. Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes[J]. Breast Cancer Res Treat, 2018, 169(2): 267-275. doi:10.1007/s10549-018-4678-1.
[30] Evans R E. Survival and Biomarker Trends for Non-small Cell Lung Cancer with the Implementation of Cuban Developed Therapies[D]. State University of New York at Buffalo, 2020.
[31] Yang W, Zhou J, Zhang K, et al. Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma[J], 2021, 12(9): 2702-2714.
[32] Mehdi A, Rabbani S A. Role of Methylation in Pro- and Anti-Cancer Immunity[J]. Cancers (Basel), 2021, 13(3). doi:10.3390/cancers13030545.